Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
There has been a lot of excitement about the potential of biosimilars at the European League Against Rheumatism Annual Congress (EULAR) in London this week. 10 June 2016
Shareholders of German family-owned pharma major Boehringer Ingelheim have decided to appoint Simone Menne to the firm’s board of managing directors with effect from September 1, 2016. 10 June 2016
The US District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen Therapeutics and Japan’s Takeda Pharmaceutical against Andrx and Actavis (now Allergan) companies. 10 June 2016
In our quarterly special report Dr Michelle Maxwell takes an in-depth look at the history of personalized medicines and their future potential. 9 June 2016
In our weekly expert view piece Sander van Deventer, managing partner of Forbion Capital Partners, analyzes the challenges facing European start-ups and asks what could be done to improve the success of small biotech companies in Europe. 7 June 2016
German family-owned drugmaker Grünenthal Group today announced that its supervisory board has named Gabriel Baertschi to become Grünenthal’s new chief executive as of October 1, 2016. 7 June 2016
Germany’s Merck (MRK: DE) and US pharma giant Pfizer (NYSE: PFE) plan to file for accelerated approval of avelumab for the treatment of patients with metastatic merkel cell carcinoma (MCC), it has been revealed. 6 June 2016
The progress that has been made globally in developing treatments for rare diseases in the last 20 years is enormous. At the end of the 20th century there were just eight medicines approved in Europe for diseases compared to around 200 today. But there is still a long way to go. 6 June 2016
Several pharmaceutical companies in India, including Dr Reddy's, have been trying for months to recover funds from Venezuela. The nation is not the only one giving sleepless nights to Indian pharma exporters, struggling to counter an expected drop in export growth, reports The Pharma Letter’s India correspondent. 2 June 2016
If the innovative approach being championed by Boston-based biopharma company Berg delivers to patients what it promises to, then it could spell the end for a number of features which characterize pharma today. 31 May 2016
Eliot Forster, who became chief executive of Immunocore in January 2015, speaks to The Pharma Letter’s Katie Osborne on why he is so excited about ImmTACs and how the company is working around the clock to get its lead product – IMCgp100 - to a group of patients with no other treatment options. 27 May 2016
Embattled drug company Valeant has named Tyco International executive Sam Eldessouky as corporate controller and a senior vice president as it tries rebuild its reputation after a string of controversies. 27 May 2016
Conversations about barriers which researchers face in getting cell and gene therapies to patients are dominated by dialogue on trial data, regulators, finance and commercialization, as well as the science itself. But another area which has to be brought up to scratch before this wave of treatments can deliver on their promise is the supply chain. 26 May 2016
US biotech Gilead Sciences has added two names to its senior leadership team, with Kevin Young taking on the chief operating officer role and Martin Silverstein becoming executive vice president for strategy. 25 May 2016
US drugmaker Ariad Pharmaceuticals has appointed Jennifer Herron as executive vice president, chief commercial officer, effective May 31, 2016. 25 May 2016
UK biotech Silence Therapeutics has announced a number of changes to its management as it positions itself as a leading RNA technology company. 25 May 2016
In our weekly expert view piece, Ed Corbett, engagement manager at specialist pharmaceutical strategy consultants, Novasecta, examines the British biotech landscape. 24 May 2016